According to the latest VC report, the region is continuing its upswing in funding raises, and experts are cautiously optimistic about the rest of the year.
/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug.